COMPASS Pathways (NASDAQ: CMPS) is one of 886 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare COMPASS Pathways to related companies based on the strength of its analyst recommendations, risk, earnings, institutional ownership, profitability, valuation and dividends.
This is a breakdown of recent ratings and target prices for COMPASS Pathways and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|COMPASS Pathways Competitors||4985||18508||40311||777||2.57|
Institutional & Insider Ownership
18.7% of COMPASS Pathways shares are held by institutional investors. Comparatively, 44.9% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.4% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares COMPASS Pathways and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|COMPASS Pathways||N/A||-$60.33 million||-8.98|
|COMPASS Pathways Competitors||$1.70 billion||$122.33 million||-2.41|
COMPASS Pathways’ competitors have higher revenue and earnings than COMPASS Pathways. COMPASS Pathways is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares COMPASS Pathways and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|COMPASS Pathways Competitors||-3,674.62%||-115.85%||-26.81%|
COMPASS Pathways competitors beat COMPASS Pathways on 7 of the 12 factors compared.
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.